Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced the online publication of a special supplement Nature Outlook: Medical Imaging which will appear in the 31 October issue of Nature, and in which new collaborative data from proof-of-principle studies of the Company’s Manocept™ platform will be featured. The supplement produced with the support of Navidea includes a White Paper entitled “Innovations in receptor-targeted precision imaging at Navidea: Diagnosis up close and personal” which provides new insights into the use of Cy3-tilmanocept, a fluorescent-labeled agent derived from the same platform underlying the Company’s Lymphoseek ® (technetium 99m tilmanocept) Injection product. The online edition also includes several peer-reviewed articles published previously by Nature Publishing Group that reinforce the principle of CD206 mannose receptor targeting using Manocept compounds to identify macrophages. This principle supports the potential broad application of novel Manocept agents for diagnosis and staging across a range of disease states, including Kaposi’s sarcoma, rheumatoid arthritis, tuberculosis, metastatic disease, systemic lupus erythrematosus, and vascular inflammation, among others.
“We are extraordinarily pleased to highlight the capability of our Manocept platform in N ature magazine,” commented Dr. Mark Pykett, Navidea CEO. “We believe this platform may unfold important new opportunities for the Company across a range of clinical indications where significant unmet medical need exists. Having already made substantial investment in the underlying approach for our approved product Lymphoseek, we believe the applications enabled by the Manocept platform have the potential to significantly expand the commercial potential of our technology and franchise. We believe now is the appropriate time to leverage the platform and accelerate realization of its additional potential. With a recently completed financing to augment our balance sheet as product revenue advances, we believe the Manocept platform is well-positioned for near-term progress and look forward to unfolding new opportunities in the near future.”
“The collaborative studies presented in this Nature publication focused on establishing the ability of a fluorescent-labeled tilmanocept to target macrophages in three disease states which are representative of broader macrophage-associated disorders: Rheumatoid Arthritis (RA), Kaposi’s Sarcoma (KS) and Tuberculosis (TB),” said Frederick Cope, PhD, FACN, Senior Vice President and Chief Science Officer at Navidea. “The data indicate that CD206-targeting using Manocept-derived molecules may prove to be a potent tool for addressing unmet clinical needs such as localizing, staging and assessing disease activity in multiple therapeutic areas.”